Clinical Trials Directory

Trials / Withdrawn

WithdrawnNCT02378142

Pazopanib for Treating Uterine Leiomyosarcoma

A Phase II Evaluation of Pazopanib in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus

Status
Withdrawn
Phase
Phase 2
Study type
Interventional
Enrollment
0 (actual)
Sponsor
Gynecologic Oncology Group · Network
Sex
Female
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to test any good and bad effects of the study drug pazopanib.

Conditions

Interventions

TypeNameDescription
DRUGPazopanib

Timeline

Start date
2015-03-01
Primary completion
2018-01-01
First posted
2015-03-04
Last updated
2015-11-18

Source: ClinicalTrials.gov record NCT02378142. Inclusion in this directory is not an endorsement.

Pazopanib for Treating Uterine Leiomyosarcoma (NCT02378142) · Clinical Trials Directory